Neurogene (NGNE) Operating Expenses (2013 - 2026)

Neurogene has reported Operating Expenses for 14 years, with the latest figure at $33.3 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 28.67% year-over-year to $33.3 million; the trailing twelve-month figure through Mar 2026 stood at $110.8 million (up 22.15% YoY), and the FY2025 full-year result was $103.3 million, up 23.7% from the prior year.
• Operating Expenses for Q1 2026 stood at $33.3 million, up from $27.5 million in the prior quarter.
• The five-year high for Operating Expenses was $33.3 million in Q1 2026, with the low at $11.7 million in Q4 2022.
• Historically, Operating Expenses has averaged $19.5 million across 5 years, with a median of $18.8 million in 2024.
• Annual changes were most pronounced in 2022 — Operating Expenses retreated 23.09% — and 2024, when it jumped 67.19%.
• Neurogene's Operating Expenses stood at $11.7 million in 2022, then grew by 26.24% to $14.7 million in 2023, then soared by 46.01% to $21.5 million in 2024, then climbed by 27.97% to $27.5 million in 2025, then grew by 21.14% to $33.3 million in 2026.
• The last three Operating Expenses figures came in at $33.3 million (Q1 2026), $27.5 million (Q4 2025), and $23.8 million (Q3 2025), per Business Quant data.